Nigel Richard Parker

Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The company is based in Osaka, Japan.

Part of IQVIA Holdings, Inc., Walsh International, Inc. is a company that develops marketing and sales information systems. The company is based in Newtown, PA. Walsh International was acquired by Cognizant Corp on August 31, 1998 for $184.63 million.

AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Helmholtz-Gemeinschaft Deutscher Forschungszentren eV operates as a scientific research organization. It performs cutting-edge research which contributes substantially to solving the grand challenges of science, society, and industry. The firm focuses on six research fields: Energy, Earth and Environment, Health, Key Technologies, Structure of Matter plus Aeronautics, Space, and Transport. It develops research programs for each of these fields. The company was founded in 1995 and is headquartered in Berlin, Germany.

Part of Bayer AG, Bayer Innovation GmbH conducts creative pharmaceutical research. The company is based in Dusseldorf, Germany. The CEO of the German company is Detlef Wollweber.

Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany.

Bundesverband der Deutschen Industrie e.V. provides information on the German industry, economy, and economic policies. The private company is based in Berlin, Germany. The German company organizes events that bring together business, politics, science, and civil society for discussions, whether virtually, in-person, or hybrid. The company was founded by Gerhard Schempp.

Conseil Européen de l'industrie Chimique, also known as the European Chemical Industry Council (Cefic), is a non-profit organization that represents large, medium, and small chemical companies across Europe. The non-profit company was founded in 1972 and is based in Brussels, Belgium, with subsidiaries in Belgium. Cefic is committed to the UN sustainability agenda and has developed a unique roadmap, called the Transition Pathway, to guide the European chemicals industry through the massive transformation needed to meet the EU Green Deal goals. The Transition Pathway lays out more than 200 actions for the EU institutions, Member State governments, and industry to build the business case for investing in sustainability. Cefic provides clarity, predictability, and direction to guide the industry through the transition.

Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom.

Takeda Europe Research & Development Centre is a British company that specializes in Biological Research. The private company is based in London, UK.

Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland.

Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany.

Founded in 1934, Bayer Real Estate GmbH is a subsidiary of Bayer AG that engages in the management of land, buildings, and apartments. The company is based in Leverkusen, Germany.

Verband Forschender Arzneimittelhersteller eV, founded in 1994, is an association of researching pharmaceutical companies in Germany. The private company is based in Berlin, Germany. The German company's main focus is on the drugs and therapies currently being researched in the industry.

Zeneca Pharmaceuticals manufactures medicines.

Linear Diagnostics Ltd. operates as a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. It specializes in molecular diagnostics, novel technology and optical detection. The company was founded by Matt Hicks in 2011 and is headquartered in Birmingham, the United Kingdom.

Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021.

Part of Ferring Ventures, FinVector Oy is a Finnish biopharmaceutical company that specializes in manufacturing viral-based gene therapy products. The company is based in Kuopio, Finland, and has extensive experience in cgmp manufacturing. FinVector employs hundreds of highly qualified professionals from over 40 different countries and works on cutting-edge biopharmaceuticals. It has invested in building state-of-the-art gmp facilities for viral vector platforms. The company was founded in 1993 by Seppo Ylä-Herttuala, and the CEO is Giuseppe Carloni.